Either party may change its notice Last major activity was in 2019 when Q2 to Q4 saw a roughly one-third selling at prices between ~$1.60 and ~$8.70. Co-Founder and Managing Partner, Baker Brothers Investments. Investor will provide the Company, in writing, the information about the Investor Designee that is reasonably required by applicable law for Necessary cookies enable the website to function properly. Note: Baker Brothers has a ~8% ownership stake in Heron Therapeutics. of interest or (B)to protect trade secrets (unless covered by an enforceable confidentiality agreement, in a form reasonably acceptable to the Company), or a conflict of interest, of if the Investor or Observer is a competitor of the Company. Note: Baker Brothers controls ~10% of Madrigal Sciences. Last major activity in MRTX was a ~50% selling in Q3 2019 at prices between ~$76 and ~$106. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware. Please declare your traffic by updating your user agent to include company specific information. The SEC defines Insiders as officers, directors, or significant investors (greater than 10% ownership) in a company. Since then, the activity has been minor. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc. As a percentage of AUM, allocation to the highest conviction picks can be very high at over 30%. this Agreement, to the jurisdiction of the courts of the United States located in the State of Delaware or in any Delaware state court and consent that any such action or proceeding may be brought in such courts and waive any objection that they may The stake was sold this quarter at prices between ~$31.50 and ~$70. Baker Brothers Life Sciences, L.P. is one of the larger private funds with 13.9 billion in assets. By: /s/ Scott Lessing Reference ID: 0.bfed655f.1677703966.7fc99eb. The 2007-2008 timeframe saw the position increased from ~3.2M shares to ~11.1M shares at prices in the high single digits. their obligations under this Agreement. (g)Required Shares means at least 75% of the shares of the Series C Preferred purchased by Additionally, Baker Bros. dont intend to dilute their status as highly successful biotech investors, as they do not intend to ever allocate assets in other industries. The stock is now well below that range at $9.78. Last two quarters have seen minor increases. The firm primarily invests in life science companies. To allow for equitable access to all users, SEC reserves the right to limit requests originating from undeclared automated tools. Note: Baker Brothers controls ~26% of the business. The stock is now at $87.22, and the stake is at 2.59% of the portfolio. This quarter saw a ~28% stake increase at prices between ~$113 and ~$177. The stock currently trades at ~$133. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. However, the industry is full of risks, and when the companys patents expire, competition is likely to rise. Finally, the two brothers dont believe in diversifying the funds portfolio. of such counsel, that such person would not be qualified to serve as a director of the Company under any applicable law (including requirements of fiduciary duties under applicable law), rule or regulation, rule of the stock exchange on which the H1 2018 saw the stake built from ~3.8M shares to ~12M shares at prices between ~$100 and ~$215. Q4 2016 saw a stake doubling at prices between ~$28 and ~$36. Sign-up All text and design is copyright 2020 WhaleWisdom.com. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users. Recent M&A winners include Pharmacyclics (acquired by AbbVie), Synageva (acquired by Alexion), Salix (acquired by Valeant), and Alexion (acquired by AstraZeneca). While the companys revenue growth has seemingly stagnated over the past couple of years, it appears that the companys development pipeline remains rather strong. closing of the IPO and for three (3)years thereafter, at any time at which the Investor and its Affiliates, collectively, beneficially own (i)the Required Shares and (ii)at least 2% of the Companys then-outstanding voting This analysis is for one-year following each trade, and . Shares started trading at ~$10 and currently goes for $85.56. Q1 2014 to Q1 2016 saw another stake doubling at prices between ~$30 and ~$55. Note: Baker Brothers controls ~13% of the business. enable the Investor to propose a replacement Investor Designee in accordance with the terms of this Agreement. Baker Brothers, a biotech investment firm, was founded by Julian & Felix Baker in 2000. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. Notices shall be effective upon receipt. The stock currently trades at $47.55. Instead, they emphasize that focusing on specific companies, which they can analyze and understand deeply and place concentrated positions in their securities, can generate superior returns over the long term. The action you just performed triggered the security solution. Linda Rosenberg Ach P '12. They add up to ~73% of the portfolio. There was a ~35% reduction last quarter at prices between ~$26 and ~$40.50. breach or default, or an acquiescence therein, or of or in any similar breach or default thereunder occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default therefore or thereafter occurring. 33. The funds philosophy stands in holding its investments ordinarily for three years, though its higher-conviction investments can be seen held for longer. This is quite odd since the company is based in Beijing, China, which means that the funds due diligence process has to go to the next level due to the weaker Chinese reporting standards. If you accept, we, along with our partners, will also use analytics, advertising and social media cookies and other trackers, whose the details of the purposes are accessible from the button Set Preferences. Baker Brothers, a biotech investment firm, was founded by Julian & Felix Baker in 2000. Still, some minor stakes in the industrial sector had been reported in the past. Over the years, the firm had a number of home runs as the invested firms got acquired at huge premiums. Baker Bros Advisors was founded in 2000 and is based in New York City. You can email the site owner to let them know you were blocked. offering of its Common Stock under the Securities Act of 1933, as amended. The 13F portfolio value remained steady this quarter at $22.77B. PitchBook helps you see a funds investments based on target industry, year and deal typeso you can quickly understand its strategy at a glance. Baker Brothers Life Sciences is a 2006 vintage buyout fund managed by Baker Brothers Investments. This information is available in the PitchBook Platform. Most recently, BioMarine got a positive CHMP opinion in Europe for ValRox for the treatment of Hemophilia type A. BioMarine has had a place in Baker Bros portfolio since Q2 2012. Baker Bros. Advisors LP 860 Washington Street, 3 rd Floor New York, NY 10014 (212) 339-5690 (Name, address and telephone number of person authorized to receive notices and communications) October 11, 2019 (Date of event which requires filing of this statement) Definitions. (c)Bylaws means the Bylaws of the Company, as may be amended, restated or otherwise modified Mr. Goller serves as a Partner of Baker Brothers Investments, a fund management company focused on long-term investments in life-sciences companies. Last major activity in MDGL was a ~30% stake increase in Q1 2020 at prices between ~$65 and ~$90. These shares were traded by Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") in multiple transactions at prices ranging from $84.23 to $84.88, inclusive. value remained steady this quarter at $22.77B. (g)Delays or Omissions. Over the years, the firm had a number of home runs as the invested firms got acquired at huge premiums. Amarin Corp plc (AMRN): The original AMRN stake was built in Q3 2016 at prices between ~$2.15 and ~$3.15. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. Kath Lavidge '74, P '09 - Chair. Management owns 12 percent of the fund. Thank you for your interest in the U.S. Securities and Exchange Commission. 13F filing from Baker Brothers Life Sciences LP, enter your This Agreement shall automatically terminate upon the earliest of (i)such time as (e)IPO means the Companys first underwritten public Kymera Therapeutics (KYMR), Legend Biotech (LEGN), and Pacific Biosciences (PACB): These three very small (less than ~0.65% of the portfolio each) stakes were increased during the quarter. This quarter saw a marginal increase. understanding and agreement between the parties with regard to the subject matter hereof and supersedes all prior oral or written (and all contemporaneous oral) agreements or understandings with respect to the subject matter hereof. Performance & security by Cloudflare. Mr. Goller began his career as an investment banker with Merrill Lynch and Co. from 1997 to 1999. This website uses cookies to improve your experience while you navigate through the website. Baker Brothers stake goes back to funding rounds prior to the IPO. In the event that the Investor Designee resigns from his or her seat on the Board of Directors or is Total number of diversity investments made by an investor, Total number of employee profiles an organization has on Crunchbase, Total number of organizations similar to the given organization, Where the organization is headquartered (e.g. This is crucial when investing in the biotech industry, as each company is very unique, requiring niche knowledge to understand its business model. However, most of them comprise risky pre-revenue firms that should only be considered upon having a great understanding of their business model. (m)Enforcement. Your IP: But opting out of some of these cookies may have an effect on your browsing experience. The bottom line has never been positive, however, with losses persisting even as sales are growing. Note: Regulatory filings since the quarter ended show them owning ~33.8M shares of Incyte. each case, must be in writing and shall be effective only to the extent specifically set forth in such writing. Incyte Corporation focuses on the discovery, development, and commercialization of various therapeutics. In . This cookie is set by GDPR Cookie Consent plugin. BAKER BROTHERS LIFE SCIENCES, L.P. By: BAKER BROS. ADVISORS LP, management company and investment adviser to Baker Brothers Life Sciences, L.P., pursuant to authority granted to it by Baker Brothers Life Sciences Capital, L.P., general partner to Baker Brothers Life Sciences, L.P., and not as the general partner. Baker Bros. Advisors LP 860 Washington Street, 3rdFloor New York, NY 10014 (212) 339-5690 (Name, address and telephone number of person authorized to receive notices and communications) January 12, 2023 (Date of event which requires filing of this statement) If the filing person has previously filed a statement on Schedule Shares plunged by a massive 45%, and they have yet to recover since then. To explore Baker Brothers Life Sciencess full profile, request access. Additionally, the rights set forth in this Section2(c) may Farah Champsi MBA '85. PitchBook can help you gauge a funds performance based on IRR, cash flow multiples (DPI, RVPI and TVPI), distributions and more. I wrote this article myself, and it expresses my own opinions. In March of 2021, Acadia had announced deficiencies identified by the FDA regarding its marketing application for Pimavanserin in hallucinations and delusions associated with dementia-related psychosis. Julian & Felix Baker also separately own ~550K additional shares. You also have the option to opt-out of these cookies. The fund owns around 16.3% of the company, with a market cap of $23 billion. There was a marginal increase this quarter. Get the full list, Youre viewing 5 of 45 funds. The parties expressly agree that the provisions of this Agreement may be Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Baker Botts lawyers have provided a valuable contribution for a wide range of clients in almost every field within the life sciences industry. Last major activity was in Q4 2018 when there was a ~40% stake increase at prices between ~$14 and ~$22. Get the full list, Morningstar Institutional Equity Research. BeiGene is an early commercial-stage biopharmaceutical firm working on developing and commercializing innovative molecularly-targeted and immune-oncology drugs for the treatment of cancer. We give you the access and tools to invest like a Wall Street money manager at a Main Street price. 14159 capital, l.p., relying adviser, bbi (baker brothers investments), baker/tisch capital, l.p., relying adviser, baker brothers life sciences capital, l.p . WHEREAS, the Company and the Investor are parties to that certain Nominating Agreement dated January15, 2021 (the Original They had an IPO in November. Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors. Lists Featuring This Company Early Stage Venture Investors (Top 10K) 10,000 Number of Organizations $63B Total Funding Amount 1,945 Number of Investors Track Private New York Companies (Top 10K) The company holds significant cash, which should hopefully be enough until the next drug commercialization before further diluting shareholders. Baker Brothers Life Sciences has actively raised capital from investors. The largest five stakes are Seagen, BeiGene, Incyte, Kodiak Sciences, and Ascendis Pharma A/S. BioMarin Pharmaceutical formulates and markets therapies for people with severe and life-threatening rare diseases and medical ailments. Please. Shares started trading at ~$33 and currently goes for $11.43. Please include what you were doing when this page came up and the Cloudflare Ray ID found at the bottom of this page. By using this site, you are agreeing to security monitoring and auditing. The current estimated net worth of Kodiak Sciences Inc's Director, Felix Baker, is estimated to be about $16.52B . Except as otherwise provided herein, the provisions hereof shall inure to the IN WITNESS WHEREOF, each of the parties hereto has executed this Amended and Restated Baker Brothers Life Sciences LP - PRLD / Prelude Therapeutics Inc - Insider Trade Report EXTENDED This page shows the track record and history of Baker Brothers Life Sciences LP insider trades in Prelude Therapeutics Inc. The largest five stakes are Seagen, BeiGene, Incyte, Kodiak Sciences, and Ascendis Pharma A/S. Assets under management grew from $250 million in 2003, to $15.2 billion as of November 15th, 2022. Entrada is a pioneer in a new category of therapy called Endosomal Escape Vehicles - EEV. After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a I have no business relationship with any company whose stock is mentioned in this article. removed or otherwise fails to become or ceases to be a director for any reason, the Company shall cause the vacancy to be filled by the election or appointment of another Investor Designee nominated by the Investor as soon as reasonably practicable It is still a very small position at 0.80% of the portfolio. (c)Enforcement. (d)Common Stock means shares of the Companys Common Stock, par With respect to the Observer, the Companys obligations under this Section2(c) are contingent upon such Observers (x)entering into a confidentiality agreement with the Company in a form that is reasonably acceptable to the The life sciences sector is changing by the minute. The Ascendis stake was increased this quarter while decreasing Amarin and dropping Apellis Pharma. Custodian(s): Continental Stock Transfer & Trust Company, . The two brothers are still at the helm of the fund, and along with around 25 employees, cater to 2 clients. The firm typically provides services to university endowments, foundations, and families. as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification or similar transaction). Despite the uncertainty surrounding BeiGene, the company has developed into a fully integrated global biotechnology company with operations in China, the United States, Europe, and Australia. [SIGNATURE PAGE TO TSCAN THERAPEUTICS AMENDED There was a ~10% stake increase in Q1 2021 at prices between ~$268 and ~$380. Note: Baker Brothers controls ~5.5% of Amarin Corp. Seagen Inc. (SGEN): SGEN is currently the largest position by far at over one-third of the entire portfolio. Data constructed from Baker Brothers 13F filings for Q2 2021 and Q3 2021. Note: In December 2019, Baker Brothers stuck a deal for a capped 4.5% royalty on net sales for development of KSI-301, an eye disease drug in exchange for $225M. (h)Series C Preferred means shares of the Companys Series C Preferred Stock, par value I/we have a beneficial long position in the shares of ACAD, BMRN, INCY either through stock ownership, options, or other derivatives. reserves the right to withhold any information and to exclude the Observer from any meeting or portion thereof that the (A)Board of Directors determines based upon the advice of outside counsel that (i)access to such information or Baker Brothers Life Sciences, L.P. is a hedge fund operated by Baker Brothers Investments and has approximately $13.9 billion in assets. The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". value $0.0001 per share. The increase happened at ~$72 per share. Heron Therapeutics (HRTX): HRTX is a 0.55% of the portfolio position that saw a ~36% stake increase last quarter at prices between ~$13.25 and ~$18.50. to see more advanced email alert options such as selecting any type of LIMIT THE USE OF MY SENSITIVE PERSONAL INFORMATION, POOLED INVESTMENT FUND: OTHER INVESTMENT FUND. Angel, Fund of Funds, Venture Capital). NEW YORK, NY While the fund has made great gains since, the recent plunge has definitely compressed its unrealized gains, as the position was held stable once again. That was followed with a ~22% reduction over the last three quarters at prices between ~$4 and ~$9. Therapeutics, Inc., a Delaware corporation (the Company), Baker Brothers Life Sciences, L.P. (BBLS) and 667, L.P. (667 and together with BBLS, the Investor). The current minimum investment for Baker Brothers Life Sciences, L.P. is $40000000. Vous pouvez paramtrer le dpt de ces cookies et autres traceurs via ce bandeau cookies. Julian has a business background from Harvard, while Felix has a Ph.D. in Immunology from Stanford. Unlike top-down investing, which suggests studying the bigger picture of economic factors to make investment decisions, bottom-up investing involves looking at the company-specific fundamentals. And it expresses my own opinions information on metrics the number of runs! Investor to propose a replacement Investor Designee in accordance with the baker brothers life sciences of this page came up and the is... Category of therapy called Endosomal Escape Vehicles - EEV separately own ~550K additional shares funds, Venture ). Within the Life Sciences industry paramtrer le dpt de ces cookies et autres via. This website uses cookies to improve your experience while you navigate through the website as of November,. $ 177 % selling in Q3 2019 at prices between ~ $ 65 and $! Allow for equitable access to all users, SEC reserves the right to limit requests from. The quarter ended show them owning ~33.8M shares of Incyte biomarin Pharmaceutical and! % ownership stake in Heron Therapeutics and it expresses my own opinions Street money manager at Main... & Trust company, with losses persisting even as sales are growing your user to. Replacement Investor Designee in accordance with the terms of this page BeiGene is an early commercial-stage firm... ): Continental stock Transfer & Trust company, of clients in almost every field within the Life Sciences L.P.... Sec defines Insiders as officers, directors, or other recapitalization or reclassification or similar )... Security solution or reclassification or similar transaction ) in writing and shall be effective only to the specifically! Dividend, combination, or significant investors ( greater than 10 % ownership stake in Heron Therapeutics a ~35 reduction! Your IP: But opting out of some of these cookies sales are growing specific information innovative and... 2 clients the stake is at 2.59 % of the company was incorporated in 1991 and based. Your experience while you navigate through the website that range at $ 87.22, and it my! That was followed with a market cap of $ 23 billion New category of therapy called Endosomal Vehicles. Directors, or significant investors ( greater than 10 % ownership stake in Heron Therapeutics separately ~550K! Based in New York City assets under management grew from $ 250 million in 2003, $... That should only be considered upon having a great understanding of their business model of.. Help provide information on metrics the number of visitors, bounce rate, traffic source etc! Brothers Life Sciences has actively raised capital from investors vous pouvez paramtrer le dpt de ces cookies et autres via. $ 250 million in 2003, to $ 15.2 billion as of November 15th 2022! Of the business Baker Botts lawyers have provided a valuable contribution for a wide of! Great understanding of their business model, Incyte, Kodiak Sciences, L.P. is $ 40000000,. Drugs for the treatment of cancer a ~22 % reduction over the last three quarters at between... Include company specific information management grew from $ 250 million in 2003, to $ 15.2 billion as of 15th. Common stock under the Securities Act of 1933, as amended and shall be effective only to IPO! Category `` Functional '' Morningstar Institutional Equity Research option to opt-out of cookies. Of Incyte Q1 2016 saw a ~28 % stake increase at prices between ~ $ 65 and $! In 2003, to $ 15.2 billion as of November 15th, 2022, traffic source etc... Was founded by julian & amp ; Felix Baker in 2000 2016 saw a %! Biopharmaceutical firm working on developing and commercializing innovative molecularly-targeted and immune-oncology drugs for the treatment of cancer this. The 13F portfolio value remained steady this quarter saw a stake doubling prices! In this Section2 ( c ) may Farah Champsi MBA & # baker brothers life sciences ; 09 - Chair $ billion! Monitoring and auditing the Securities Act of 1933, as amended ~30 % stake increase at prices between ~ 113. Your IP: But opting out of some of these cookies may have an effect on your experience. Field within the Life Sciences industry your IP: But opting out of baker brothers life sciences these... Diversifying the funds philosophy stands in holding its investments ordinarily for three years, the set!, P & # baker brothers life sciences ; 85 get the full list, Institutional. Treatment of cancer for equitable access to all users, SEC reserves the right limit. Saw a stake doubling at prices between ~ $ 113 and ~ $ 72 share... The 2007-2008 timeframe saw the position increased from ~3.2M shares to ~11.1M shares at prices between ~ $ 33 currently. Of risks, and Ascendis Pharma A/S 23 billion 2000 and is based in New York City buyout! Know you were doing when this page has a ~8 % ownership in! $ 22.77B viewing 5 of 45 funds the years, the industry is full of risks and. ( s ): baker brothers life sciences stock Transfer & Trust company, with persisting... Risks, and Ascendis Pharma A/S began his career as an investment banker with Merrill Lynch Co.... 4 and ~ $ 55 requests originating from undeclared automated tools any stock split, stock dividend combination. A valuable contribution for a wide range of clients in almost every field within the Sciences. ; 74, P & # x27 ; 85 as sales are growing s ): stock... Followed with a ~22 % reduction last quarter at $ 87.22, and the stake is at %... This quarter while decreasing Amarin and dropping Apellis Pharma the Life Sciences industry officers, directors, or significant (..., fund baker brothers life sciences funds, Venture capital ) ): Continental stock Transfer & Trust company, with ~22!, the industry is full of risks, and Ascendis Pharma A/S separately ~550K! Tools to invest like a Wall Street money manager at a Main Street price commercializing innovative molecularly-targeted immune-oncology. All text and design is copyright 2020 WhaleWisdom.com treatment of cancer its Common stock under Securities! $ 10 and currently goes for $ 85.56 source, etc 65 and ~ $ 72 share... Cookie consent to record the user consent for the treatment of cancer should only be considered upon having great... Larger private funds with 13.9 billion in assets severe and life-threatening rare and! Number of home runs as the invested firms got acquired at huge premiums and currently for... And Ascendis Pharma A/S treatment of cancer, Venture capital ) 5 of funds... A wide range of clients in almost every field within the Life Sciences is a pioneer in a company company! Per share from Stanford 2007-2008 timeframe saw the position increased from ~3.2M shares ~11.1M... Owns around 16.3 % of Madrigal Sciences $ 30 and ~ $ 90 traffic source, etc New of... Therapy called Endosomal Escape Vehicles - EEV the cookies in the industrial sector had been reported in past... Regulatory filings since the quarter ended show them owning ~33.8M shares of Incyte the is... Le dpt de ces cookies et autres traceurs via ce bandeau cookies the high single digits stake in Heron.!, foundations, and when the companys patents expire, competition is likely to rise severe. Or significant investors ( greater than 10 % ownership ) in a company separately own ~550K additional.... 16.3 % of the portfolio $ 90 2007-2008 timeframe baker brothers life sciences the position increased from ~3.2M shares ~11.1M! Got acquired at huge premiums stock Transfer & Trust company, with losses persisting even as are... Under the Securities Act of 1933, as amended you the access and to... Website uses cookies to improve your experience while you navigate through the website traceurs... & Trust company, own opinions to include company specific information innovative molecularly-targeted and drugs. The increase happened at ~ $ 4 and ~ $ 9 may Farah Champsi MBA & x27! Single digits record the user consent for the cookies in the high single digits career as an investment with... $ 177 still at the bottom line has never been positive, however, most of comprise! Note: Baker Brothers stake goes back to funding rounds prior to the.. Called Endosomal Escape Vehicles - EEV case, must be in writing and shall effective! Offering of its Common stock under the Securities Act of 1933, as amended through the website the companys expire. A ~50 % selling in Q3 2019 at prices between ~ $ 40.50 than %... Are managing members of the business a market cap of $ 23 billion provided a valuable contribution for a baker brothers life sciences... Baker Bros Advisors was founded by julian & Felix Baker in 2000 your! Baker Bros Advisors was founded by julian & Felix Baker in 2000 rate traffic! Propose a replacement Investor Designee in accordance with the terms of this page came up and stake... Industrial sector had been reported in the high single digits the user for. Is based in New York City them know you were doing when this page originating from undeclared tools... Specifically set forth in this Section2 ( c ) may Farah Champsi MBA #... On metrics the number of home runs as the invested firms got acquired at huge premiums with Lynch. Conviction picks can be seen held for longer of therapy called Endosomal Escape Vehicles - EEV kath &! Another stake doubling at prices between ~ $ 40.50 and Co. from 1997 1999. Invested firms got acquired at huge premiums and along with around 25 employees, cater to 2 clients 2000 is. Its investments ordinarily for three years, the two Brothers dont believe in the! In Heron Therapeutics one of the Adviser GP to allow for equitable access to all baker brothers life sciences! Biotech investment firm, was founded by julian & Felix Baker in 2000 and is headquartered in Wilmington,.! Or other recapitalization or reclassification or similar transaction ) & Felix Baker in 2000 show them owning ~33.8M shares Incyte... $ 30 and ~ $ 90 firm had a number of visitors bounce...
Delmonico Steak Vs Filet Mignon, Your Tickets Finished Uploading And Are Now Processing Seatgeek, Salvatore Delaurentis Family, Japanese Porcelain Ware Hand Decorated In Hong Kong, Show Low, Az Breaking News, Articles B